Clinical Trials Logo

Clinical Trial Summary

The purpose of this study is to measure the amount of a protein in the brain known as tau using an imaging procedure called Positron Emission Tomography (PET/CT). Tau has been shown to build up in the brains of patients with injury to brain cells. This study looks at neurodegenerative diseases such as frontotemporal degeneration (FTD).


Clinical Trial Description

The purpose of this study is to measure the amount of a protein in the brain known as tau using an imaging procedure called Positron Emission Tomography (PET/CT). Tau has been shown to build up in the brains of patients with injury to brain cells, including Alzheimer's disease, Parkinson's disease, Lewy body disease and Frontotemporal degeneration. 18F-AV-1451 (formally known as 18F-T807) is a specialized radioactive PET tracer that sticks to the tau protein in the brain. In this study, researchers will use 18F-AV-1451 to form images of tau binding in the brain. 18F-AV-1451 is an investigational or experimental imaging agent that has not yet been approved by the Food and Drug Administration for use in brain imaging. In this study, researchers want to find out how accurate and useful 18F-AV-1451 is in imaging patients who have problems with thinking, remembering, speech, and visual activities, and may be diagnosed with different types of neurodegenerative disease. This study will help test how imaging measures may provide information that could be used to determine diagnosis for patients in the future. The results of the PET/CT scan will be compared with other information obtained under related protocols, including brain magnetic resonance imaging (MRI), spinal fluid and cognitive test results. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT03143374
Study type Interventional
Source University of Pennsylvania
Contact Dahlia Kamel
Phone 215-662-6134
Email kamel.dahlia@pennmedicine.upenn.edu
Status Recruiting
Phase Phase 2/Phase 3
Start date September 2016
Completion date December 2025

See also
  Status Clinical Trial Phase
Enrolling by invitation NCT02402426 - Brain Health Registry: An Online Registry to Identify and Assess Subjects for Brain Research
Completed NCT00714636 - Cerebrospinal Fluid Repository N/A
Active, not recruiting NCT00907283 - Ferrochelating Treatment in Patients Affected by Neurodegeneration With Brain Iron Accumulation (NBIA) Phase 2
Terminated NCT00718003 - Noninvasive Examination of the Work of Breathing in Patients With Amyotrophic Lateral Sclerosis (ALS). N/A
Completed NCT00016562 - Cause and Pathogenesis of Neurometabolic Disorders N/A
Terminated NCT00718445 - Pennsylvania Consortium: Clinical Database N/A
Recruiting NCT02869048 - Amyotrophic Lateral Sclerosis and the Innate Immune System N/A
Completed NCT00718393 - Compassionate Use of Ceftriaxone in Patients With Amyotrophic Lateral Sclerosis (ALS) N/A
Terminated NCT00718107 - Satisfaction Survey for Amyotrophic Lateral Sclerosis (ALS) Patients Comparing Rooms With and Without Assistive Technology N/A
Completed NCT00001365 - Dextromethorphan for the Treatment of Parkinson's Disease and Similar Conditions of the Nervous System Phase 2
Recruiting NCT00271622 - The Neurodevelopmental and Behavioral Phenotyping Screening Protocol
Completed NCT01758510 - Safety Study of HLA-haplo Matched Allogenic Bone Marrow Derived Stem Cell Treatment in Amyotrophic Lateral Sclerosis Phase 1
Terminated NCT00718016 - Assessment of the Cyberlink Control System for Use by the Amyotrophic Lateral Sclerosis (ALS) Patient N/A
Completed NCT00718458 - EEG-Based Brain-Computer Interface Project for Individuals With Amyotrophic Lateral Sclerosis (ALS) N/A
Completed NCT00718497 - Comparing The Cyberlink Control System to the Manual Letter Board for Communication Purposes in the ALS Patient Population N/A
Completed NCT02418546 - Electronic-health Application To Measure Outcomes REmotely Clinical Trial N/A
Completed NCT00716131 - Amyotrophic Lateral Sclerosis (ALS) Tissue Donation Program N/A